What is Opana?
Opana is a brand name of the opioid medication oxymorphone, which is most commonly used for the treatment of moderate or severe pain. The National Cancer Institute states, “ It is also used as a sedative before surgery, to help with anesthesia during surgery, during labor, and to treat anxiety caused by some medical conditions. It is made from morphine and binds to opioid receptors in the central nervous system. Opana is a type of opioid and a type of analgesic agent. Also called Numorphan and oxymorphone hydrochloride.”
This specific type of pain medication was first developed in 2006, and was approved as a long-acting opioid used to treat short-term, around the clock pain. In most cases, this medication is only prescribed to be taken for several days consecutively, seeing as it has a high potential for abuse. Even individuals who take this medication exactly as prescribed are liable to develop a physical dependence if they take it for longer than two weeks at a time.
If you or someone close to you has been suffering from an Opana use disorder, there is help available, and recovery is possible. At Immersion Recovery Center we have developed a multi-staged program of Opana addiction recovery that begins with a short stay in an inpatient detox center. Contact us today to learn more.
Is Opana Addictive?
Like the majority of opioid painkillers, Opana can be addictive and does have a high potential for misuse. Because the risks of Opana often outweigh the benefits, it is generally only utilized when other opioid painkillers have failed to provide relief.
The U.S. Food and Drug Administration states, “The product, currently marketed by Endo Pharmaceuticals, is a reformulation of the original product, designed with physicochemical properties intended to make the drug resistant to physical and chemical manipulation for abuse by snorting and injecting. While the reformulation was approved in 2011, the FDA determined that the drug did not meet the agency’s standards for being considered abuse-deterrent and therefore declined Endo’s request to include a description of abuse-deterrent properties in product labeling.”
In 2017, the FDA actually pulled the medication from the pharmaceutical market because of the risks involved. The Drug Enforcement Administration states, “The American Association of Poison Control Centers (AAPCC) reported 387 total oxymorphone exposures, 164 single exposures, and zero deaths in 2017, a decrease from 508 total case exposures (single exposures of 220) and two deaths in 2016.” Since these numbers were reported rates of Opana misuse have continued to rise. Despite the fact that the medication is no longer easily accessible, it is still being produced illegally and misused at exceedingly high rates.